High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects

J Allergy Clin Immunol. 2013 Aug;132(2):485-6.e11. doi: 10.1016/j.jaci.2013.02.032. Epub 2013 Apr 13.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Anti-Idiotypic / administration & dosage
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / immunology
  • Asthma / physiopathology
  • Asthma / therapy*
  • Biomarkers / analysis*
  • Child
  • Eosinophilia*
  • Eosinophils
  • Female
  • Humans
  • Hypersensitivity, Immediate / immunology
  • Hypersensitivity, Immediate / physiopathology
  • Hypersensitivity, Immediate / therapy*
  • Male
  • Middle Aged
  • Omalizumab
  • Treatment Outcome
  • United States
  • Young Adult

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Omalizumab